Amidst changes to the many laws altered by Brexit is uncertainty over the pharmacovigilance market. With time passing and the likelihood of a full withdrawal increasing, what shape will the medical and pharmacovigilance industry take with the UK leaving the European Union?

Increasing pressure is being placed on pharmacovigilance across the globe. While it is known for its rapid pace of advancement in best practice and technology, more is now being demanded in terms of the scope of traditional roles for employed staff and contractors.

Companies in the Life Sciences domain, regardless of whether they do business on a global or regional scale, continuously face many reporting obligations, a very prominent example being reporting on adverse drug reactions or adverse events (SUSARs).

pharmasol, a global leader in software development and product implementation for the life sciences industry, today announced a new strategic customer for its flagship product, psiXchange...